RVPH Company Profile and Key Details

RVPH has shown mixed momentum, gaining 3.94% over the past week and -41.21% over the past quarter, though year-to-date performance is up 21.08%. Short-term trend indicators are bullishly aligned (SMA20 -23.6%, SMA50 -39.87%, SMA200 -60.57%). The stock’s 14-day RSI is 24.44 (weak momentum), while the ATR of 0.02 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -86.67% below its high and over -7.11% above its low. Average 10-day trading volume of 21.83 thousand shares is below the 3-month average of 37.06 thousand, indicating normal recent market interest.

Reviva Pharmaceuticals Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $7.85. This means the shares are trading below this model’s fair value.

Reviva Pharmaceuticals Holdings, Inc. (OTC:RVPH) closed at $0.50 USD, gaining $0.01 (2.46%) from the previous close of $0.49. The stock is currently mid-range between its 52-week high and low $0.26 and $17.20. With a market capitalization of about $6.43 million, Reviva Pharmaceuticals Holdings, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.50). Key stats such as the average daily volume over the past year has been around 42.67 thousand shares, volume is running light vs its 52-week average. Headquartered in Cupertino, CA, Reviva Pharmaceuticals Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Laxminarayan Bhat, the company employs approximately 14 people and listed since December 15, 2020. Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.

Wall Street analysts project EPS growth of 34.97% annually over the next five years. The latest quarter delivered EPS of -$0.19. The next quarter is forecast at -$0.05. Next year's EPS is expected at $27.67. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $2.00. The high target offers 700.0% upside. The low target suggests 300.0% downside. The mean target is $2.50. This offers 400.0% upside. Reviva Pharmaceuticals Holdings, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended August 13, 2026, missed forecasts by -50.65%. The prior quarter beat by -50.65%. Over the last six quarters, Apple has recorded several small beats. These include -20.0% in August 14, 2025.

Reviva Pharmaceuticals Holdings, Inc. has 13.11 million shares outstanding. The public float is 11.86 million shares, elevated short interest at 14.95% of float. This equals 1.87 million shares. The short ratio is 3.35 days. Institutional investors hold 8.93% of the float. Insiders own 7.73%. SAXENA PARAG holds 1.92 million shares, Nayar Rahul has 1.92 million shares and Tenzing LLC has 1.92 million shares.

Reviva Pharmaceuticals Holdings, Inc. trades at a P/E ratio of -0.07, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at -0.0, also above market averages.

Our AI price prediction model suggests that Reviva Pharmaceuticals Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.57%, with price expected at $0.52 by September 30, 2026, within a range of $0.49 to $0.55 3-Month Outlook: Projected fall of -88.05%, reaching $0.06 by December 15, 2026, with a range of $0.00 to $0.58. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 16, 2027, within a range of $0.00 to $1.33.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) shares are up 21.08% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Reviva Pharmaceuticals Holdings, Inc. trading at a premium to the broader market with a P/E of -0.07. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.91, suggesting 1674.65% upside. Our AI forecast model points to short-term strength (3.57% over two weeks), a medium-term fall (-88.05% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.